coumarin has been researched along with Congenital Familial Lymphedema in 26 studies
2H-chromen-2-one: coumarin derivative
| Excerpt | Relevance | Reference |
|---|---|---|
| "Coumarin is not effective therapy for women who have lymphedema of the arm after treatment for breast cancer." | 9.09 | Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. ( Kugler, JW; Levitt, R; Loprinzi, CL; Michalak, JC; Mowat, RB; Novotny, P; Quella, SK; Rooke, TW; Sloan, JA; Stella, PJ; Tschetter, LK; Windschitl, H, 1999) |
| "In a randomized, double-blind, parallel group study, we compared the clinical efficacy of coumarin 90 mg/day (Group A) with 135 mg/day (Group B) in 77 women (age 35-65 years) with lymphedema of the upper limb secondary to surgery and irradiation for treatment of breast cancer." | 9.09 | Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer. ( Alcaide, A; Alcoba, C; Azcona, JM; Burgos, A; Garrido, J; Lorente, C; Moreno, E; Murillo, E; Olsina-Kissler, J; Olsina-Pavia, J; Samaniego, E; Serra, M, 1999) |
| "Although there remains some significant controversy regarding the use and benefits of coumarin (5,6-benzo-alpha pyrone), it would seem that targeted appropriate and monitored use of the drug does have a significant role in the treatment of lymphedemas." | 8.82 | Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema. ( Farinola, N; Piller, N, 2005) |
| "Coumarin is an effective pharmacological treatment, but is banned in some countries due to incidences of hepatotoxicity in rats and mice, and the rare finding of similar hepatotoxicity in humans." | 6.44 | CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients? ( Farinola, N; Piller, NB, 2007) |
| "Coumarin is not effective therapy for women who have lymphedema of the arm after treatment for breast cancer." | 5.09 | Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. ( Kugler, JW; Levitt, R; Loprinzi, CL; Michalak, JC; Mowat, RB; Novotny, P; Quella, SK; Rooke, TW; Sloan, JA; Stella, PJ; Tschetter, LK; Windschitl, H, 1999) |
| "In a randomized, double-blind, parallel group study, we compared the clinical efficacy of coumarin 90 mg/day (Group A) with 135 mg/day (Group B) in 77 women (age 35-65 years) with lymphedema of the upper limb secondary to surgery and irradiation for treatment of breast cancer." | 5.09 | Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer. ( Alcaide, A; Alcoba, C; Azcona, JM; Burgos, A; Garrido, J; Lorente, C; Moreno, E; Murillo, E; Olsina-Kissler, J; Olsina-Pavia, J; Samaniego, E; Serra, M, 1999) |
| "We conducted a randomized, double-blind, placebo-controlled, crossover trial of 5,6-benzo-[alpha]-pyrone in 31 patients with postmastectomy lymphedema of the arm and 21 patients with lymphedema of the leg of various causes (this agent, also known as 56 BaP, 1,2-benzopyrone, or coumarin, is not an anticoagulant)." | 5.07 | Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. ( Casley-Smith, JR; Morgan, RG; Piller, NB, 1993) |
| "Although there remains some significant controversy regarding the use and benefits of coumarin (5,6-benzo-alpha pyrone), it would seem that targeted appropriate and monitored use of the drug does have a significant role in the treatment of lymphedemas." | 4.82 | Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema. ( Farinola, N; Piller, N, 2005) |
| "Lympidem is a coumarin derivative which is advocated for treatment of mainly chronic lymphedema by the manufacturer." | 3.75 | Lympidem (a coumarin derivative) induced reversible hepatotoxicity in an adult Sri Lankan. ( Jayawardana, MA; Satarasinghe, RL, 2009) |
| "A study was performed on the use of an ideal phlebolymphological association (Tonka Beans, Gingko Biloba, Melilotus Officinalis) as a practical standpoint in the treatment of lymphedema of lower limbs in order to create an efficacious dose of Coumarin, Benzopyrones and Ginkolidi." | 3.69 | [Contribution of a combination of alpha and beta benzopyrones, flavonoids and natural terpenes in the treatment of lymphedema of the lower limbs at the 2d stage of the surgical classification]. ( Cataldi, A; Cerreta, G; Derwish, A; Donini, I; Occhionorelli, S; Schettino, A; Vettorello, G, 1996) |
| "Diethylcarbamazine (DEC) was studied with and without 56 BaP." | 2.67 | Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-alpha-pyrone (coumarin), and the effects of diethylcarbamazine (DEC). ( Casley-Smith, J; Casley-Smith, JR; Jamal, S, 1993) |
| "Coumarin is a secondary phytochemical with hepatotoxic and carcinogenic properties." | 2.46 | Toxicology and risk assessment of coumarin: focus on human data. ( Abraham, K; Heinemeyer, G; Lampen, A; Lindtner, O; Wöhrlin, F, 2010) |
| "Coumarin is an effective pharmacological treatment, but is banned in some countries due to incidences of hepatotoxicity in rats and mice, and the rare finding of similar hepatotoxicity in humans." | 2.44 | CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients? ( Farinola, N; Piller, NB, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (11.54) | 18.7374 |
| 1990's | 16 (61.54) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 2 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leung, EY | 1 |
| Tirlapur, SA | 1 |
| Meads, C | 1 |
| Satarasinghe, RL | 1 |
| Jayawardana, MA | 1 |
| Rockson, SG | 1 |
| Abraham, K | 1 |
| Wöhrlin, F | 1 |
| Lindtner, O | 1 |
| Heinemeyer, G | 1 |
| Lampen, A | 1 |
| Boursier, V | 1 |
| Farinola, N | 2 |
| Piller, N | 1 |
| Piller, NB | 4 |
| Landmann, C | 1 |
| Casley-Smith, JR | 8 |
| Wang, CT | 1 |
| Zi-hai, C | 1 |
| Jamal, S | 2 |
| Casley-Smith, J | 1 |
| Morgan, RG | 1 |
| Chang, TS | 1 |
| Gan, JL | 1 |
| Fu, KD | 1 |
| Huang, WY | 1 |
| Vettorello, G | 1 |
| Cerreta, G | 1 |
| Derwish, A | 1 |
| Cataldi, A | 1 |
| Schettino, A | 1 |
| Occhionorelli, S | 1 |
| Donini, I | 1 |
| Loprinzi, CL | 2 |
| Sloan, J | 1 |
| Kugler, J | 1 |
| Kugler, JW | 1 |
| Sloan, JA | 1 |
| Rooke, TW | 1 |
| Quella, SK | 1 |
| Novotny, P | 1 |
| Mowat, RB | 1 |
| Michalak, JC | 1 |
| Stella, PJ | 1 |
| Levitt, R | 1 |
| Tschetter, LK | 1 |
| Windschitl, H | 1 |
| Ganz, PA | 1 |
| Witte, CL | 1 |
| Burgos, A | 1 |
| Alcaide, A | 1 |
| Alcoba, C | 1 |
| Azcona, JM | 1 |
| Garrido, J | 1 |
| Lorente, C | 1 |
| Moreno, E | 1 |
| Murillo, E | 1 |
| Olsina-Pavia, J | 1 |
| Olsina-Kissler, J | 1 |
| Samaniego, E | 1 |
| Serra, M | 1 |
| Alder, S | 1 |
| O'Rourke, ME | 1 |
| Knight, KR | 2 |
| Hurley, JV | 1 |
| Hickey, MJ | 1 |
| Lepore, DA | 1 |
| O'Brien, BM | 2 |
| Khazanchi, RK | 1 |
| Pederson, WC | 1 |
| McCann, JJ | 1 |
| Coe, SA | 1 |
| Clodius, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study Evaluating the Safety of Bevacizumab in Women With a History of Breast Cancer Suffering From Moderate to Severe Upper Extremity Lymphedema[NCT00318513] | Phase 1 | 35 participants | Interventional | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for coumarin and Congenital Familial Lymphedema
| Article | Year |
|---|---|
The management of secondary lower limb lymphoedema in cancer patients: a systematic review.
Topics: Coumarins; Disease Management; Humans; Lower Extremity; Lymphedema; Neoplasms; Palliative Medicine; | 2015 |
Toxicology and risk assessment of coumarin: focus on human data.
Topics: Animals; Biotransformation; Chemical and Drug Induced Liver Injury; Coumarins; Edema; Flavoring Agen | 2010 |
[Lymphedema: which drug therapy?].
Topics: Anticoagulants; Breast Neoplasms; Coumarins; Diuretics; Female; Flavonoids; Humans; Lymphedema | 2002 |
Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema.
Topics: Aryl Hydrocarbon Hydroxylases; Coumarins; Cytochrome P-450 CYP2A6; Flavonoids; Humans; Lymphedema; M | 2005 |
CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients?
Topics: Animals; Chemical and Drug Induced Liver Injury; Coumarins; Humans; Liver Diseases; Lymphedema; Phar | 2007 |
Macrophage and tissue changes in the developmental phases of secondary lymphoedema and during conservative therapy with benzopyrone.
Topics: Animals; Cell Count; Coumarins; Humans; Lymphedema; Macrophages | 1990 |
8 trials available for coumarin and Congenital Familial Lymphedema
| Article | Year |
|---|---|
Treatment of filarial lymphoedema and elephantiasis with 5,6-benzo-alpha-pyrone (coumarin).
Topics: Coumarins; Double-Blind Method; Elephantiasis, Filarial; Female; Filariasis; Humans; Lymphedema; Mal | 1993 |
Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-alpha-pyrone (coumarin), and the effects of diethylcarbamazine (DEC).
Topics: Adult; Aged; Coumarins; Diethylcarbamazine; Double-Blind Method; Drug Therapy, Combination; Elephant | 1993 |
Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone.
Topics: Arm; Chronic Disease; Coumarins; Double-Blind Method; Female; Follow-Up Studies; Humans; Leg; Lymphe | 1993 |
Treatment of lymphedema by complex physical therapy, with and without oral and topical benzopyrones: what should therapists and patients expect.
Topics: Administration, Oral; Administration, Topical; Anticoagulants; Arm; Combined Modality Therapy; Couma | 1996 |
The use of 5,6 benzo-[alpha]-pyrone (coumarin) and heating by microwaves in the treatment of chronic lymphedema of the legs.
Topics: Administration, Oral; Adult; Anticoagulants; Bandages; Chronic Disease; Combined Modality Therapy; C | 1996 |
Lack of effect of coumarin in women with lymphedema after treatment for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chronic Disease; Combined Modality Therapy; Coumar | 1999 |
Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer.
Topics: Arm; Breast Neoplasms; Combined Modality Therapy; Coumarins; Dose-Response Relationship, Drug; Doubl | 1999 |
The effects of 5,6 benzo-[a]-pyrone (coumarin) and DEC on filaritic lymphoedema and elephantiasis in India. Preliminary results.
Topics: Analysis of Variance; Coumarins; Diethylcarbamazine; Double-Blind Method; Elephantiasis, Filarial; F | 1989 |
12 other studies available for coumarin and Congenital Familial Lymphedema
| Article | Year |
|---|---|
Lympidem (a coumarin derivative) induced reversible hepatotoxicity in an adult Sri Lankan.
Topics: Chemical and Drug Induced Liver Injury; Coumarins; Female; Humans; Lower Extremity; Lymphedema; Midd | 2009 |
Lymphatic research: a global concern.
Topics: Anticoagulants; Coumarins; Humans; Lymphatic Diseases; Lymphatic System; Lymphedema | 2005 |
[Successful therapy of lymphedema].
Topics: Arm; Coumarins; Humans; Leg; Lymphedema | 1994 |
[Contribution of a combination of alpha and beta benzopyrones, flavonoids and natural terpenes in the treatment of lymphedema of the lower limbs at the 2d stage of the surgical classification].
Topics: Adolescent; Adult; Aged; Anticoagulants; Coumarins; Drainage; Drug Therapy, Combination; Follow-Up S | 1996 |
Coumarin-induced hepatotoxicity.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Coumarins; Female; | 1997 |
The quality of life after breast cancer--solving the problem of lymphedema.
Topics: Breast Neoplasms; Coumarins; Female; Humans; Lymph Node Excision; Lymphedema; Postoperative Complica | 1999 |
The placebo "arm".
Topics: Coumarins; Dose-Response Relationship, Drug; Female; Humans; Lymphedema; Placebos; Randomized Contro | 1999 |
Guidelines for the surgical management of breast cancer: comment.
Topics: Anticoagulants; Breast Neoplasms; Coumarins; Female; Humans; Lymphedema; Postoperative Complications | 1999 |
Advances in symptom management: lymphedema.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Coumarins; Female; Humans; Lymphedema; Mastectomy; M | 1999 |
Combined coumarin and omental transfer treatments for canine proximal obstructive lymphoedema.
Topics: Animals; Collagen; Combined Modality Therapy; Coumarins; Dogs; Endopeptidases; Extracellular Space; | 1991 |
Coumarin and 7-hydroxycoumarin treatment of canine obstructive lymphoedema.
Topics: Animals; Coumarins; Dogs; Endopeptidases; Hindlimb; Lymph; Lymphedema; Proteins; Skin; Umbelliferone | 1989 |
The effect of coumarin (5,6 benzo-alpha-pyrone) on elicited members of the mononuclear system in dogs with chronic secondary lymphedema.
Topics: Animals; Chronic Disease; Coumarins; Dogs; Lymphedema; Monocytes; Phagocytosis | 1986 |